Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

@article{Sakata1998LatePI,
  title={Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.},
  author={Yuh Sakata and Atsushi Ohtsu and Noboru Horikoshi and Keizo Sugimachi and Yasushi Mitachi and Tetsuo Taguchi},
  journal={European journal of cancer},
  year={1998},
  volume={34 11},
  pages={1715-20}
}
S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). CDHP inhibits dihydropyrimidine dehydrogenase (DPD), an enzyme which degrades 5-FU, and maintains prolonged 5-FU concentrations in the blood and tumours. Oxo is… CONTINUE READING